Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects

Summary

This phase 1, randomized, double-blind, placebo-controlled study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of CSL730 administered by subcutaneous (SC) injection or SC infusion in healthy adult subjects.

Timeline

Start

2020-09-23

Primary completion

2023-03-28

Completion

2023-03-28

Outcome

Outcome not reported

Stopped: “Lack of clinical viability”

Drugs

Indications